N-nicotinoyl-L-tyrosin-ethyl ester | 63293-21-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-nicotinoyl-L-tyrosin-ethyl ester
• 英文别名: N-Nicotinoyl-L-tyrosin-aethylester；N-Nicotinoyltyrosine ethyl ester；ethyl (2S)-3-(4-hydroxyphenyl)-2-(pyridine-3-carbonylamino)propanoate
• CAS: 63293-21-0
• 化学式: C₁₇H₁₈N₂O₄
• 分子量: 314.341
• InChiKey: GOLHUPFAMBDSJZ-HNNXBMFYSA-N

物化性质

• 沸点：
  581.5±50.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-nicotinoyl-L-tyrosin-ethyl ester 在 乙醇 、 肼 作用下， 生成 N-nicotinoyl-L-tyrosine-hydrazide
  参考文献：
  名称：

  The Dependence of the α-Chymotrypsin-catalyzed Hydrolysis of α-N-Nicotinyl-L-tyrosinhydrazide upon the Concentration of the Buffer¹

  摘要：

  DOI：

  10.1021/ja01539a048
• 作为产物：
  描述：

  叠氮烟酸甲酰 、 L-酪氨酸乙酯 生成 N-nicotinoyl-L-tyrosin-ethyl ester
  参考文献：
  名称：

  A New Series of Substrates for the Evaluation of Chymotrypsin Activity¹

  摘要：

  DOI：

  10.1021/ja01160a085

文献信息

• Brain-specific drug delivery of steroid sex hormones cleaved from
  申请人：University of Florida

  公开号：US04900837A1

  公开（公告）日：1990-02-13

  The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula [D--DHC] (I) wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH function group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entitles [D--QC].sup.+ X.sup.- are also disclosed.

  这些化合物适用于特定部位/持续性地将中枢神经系统药物物种传递到大脑，其中包括：（a）公式[D--DHC]（I）的化合物，其中[D]是中枢神经系统药物物种，[DHC]是二氢吡啶盐氧化还原载体的还原、可生物氧化、穿过血脑屏障的脂质形式，但当[DHC]为##STR1##其中R为低级烷基或苄基，[D]为含有单个NH.sub.2或OH官能团的药物物种，当存在单个OH官能团时，其为一级或二级OH官能团，该药物物种通过NH.sub.2或OH功能团直接连接到[DHC]的羰基功能团，则[D]必须不是交感神经兴奋剂、类固醇性激素或长链烷醇；以及（b）公式（I）的化合物的非毒性药用可接受盐，其中[D]是中枢神经系统药物物种，[DHC]是二氢吡啶盐氧化还原载体的还原、可生物氧化、穿过血脑屏障的脂质形式。还公开了相应的离子吡啶盐型药物/载体[D--QC].sup.+ X.sup.-。
• Brain-specific drug delivery
  申请人：University of Florida

  公开号：US05187158A1

  公开（公告）日：1993-02-16

  The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula [D-DHC] (I) wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entities [D-QC].sup.+ X.sup.- are also disclosed.

  这些化合物适用于针对特定部位/持续释放中枢作用药物物种到达大脑，其中包括：（a）式[D-DHC]（I）的化合物，其中[D]是中枢作用药物物种，[DHC]是一种二氢吡啶的还原、可生物氧化、穿越血脑屏障的脂质形式.revreaction.吡啶盐氧化还原载体，但当[DHC]为##STR1##其中R为较低的烷基或苄基，[D]是含有单个NH.sub.2或OH官能团的药物物种，当存在单个OH官能团时，该官能团为一次级或二次级OH官能团，该药物物种直接通过所述NH.sub.2或OH官能团与[DHC]的羰基功能相连结，那么[D]必须是除了交感神经兴奋剂、类固醇性激素或长链烷醇之外的其他药物物种；以及（b）公认为无毒的药物可接受盐，其中[D]是中枢作用药物物种，[DHC]是一种二氢吡啶的还原、可生物氧化、穿越血脑屏障的脂质形式.revreaction.吡啶盐氧化还原载体的化合物的式（I）。还公开了相应的离子吡啶盐型药物/载体实体[D-QC].sup.+ X.sup.-。
• Improvements in redox systems for brain-targeted drug delivery
  申请人：University of Florida

  公开号：US05002935A1

  公开（公告）日：1991-03-26

  Inclusion complexes of hydroxypropyl-.beta.-cyclodextrin with the reduced biooxidizable, blood-brain barrier penetrating, lipoidal forms of dihydropyridine.revreaction.pyridinium salt redox systems for brain-targeted drug delivery provide a means for stabilizing the redox systems, particularly against oxidation. The reodox inclusion complexes also provide a means for decreasing initial drug concentrations in the lungs after administration of the systems, leading to decreased toxicity. In selected instances, complexation results in substantially improved water solubility of the redox systems as well.

  羟丙基-β-环糊精与可还原、可氧化的穿过血脑屏障的脂质型二氢吡啶盐氧化还原系统形成的包合物，可用于脑靶向药物传递，提供了一种稳定氧化还原系统的手段，特别是对抗氧化反应。包合物还可用于降低系统给药后肺部初始药物浓度，从而降低毒性。在某些情况下，包合物也可显著提高氧化还原系统的水溶性。
• Pharmaceutical formulations for parenteral use
  申请人：University of Florida

  公开号：US04983586A1

  公开（公告）日：1991-01-08

  Aqueous parenteral solutions of drugs which are insoluble or only sparingly soluble in water and/or which are unstable in water, combined with hydroxypropyl-.beta.-cyclodextrin, provide a means for alleviating problems associated with drug precipitation at the injection site and/or in the lungs or other organs following parenteral administration.

  在水中不溶或只微溶且在水中不稳定的药物，与羟丙基-β-环糊精结合成水性注射用制剂，可缓解在注射部位以及肺部或其他器官内药物沉淀引起的问题。
• Redox systems for brain-targeted drug delivery
  申请人：University of Florida

  公开号：US05017566A1

  公开（公告）日：1991-05-21

  Inclusion complexes of hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of .beta.- and .gamma.-cyclodextrin with the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal forms of dihydropyridine.revreaction.pyridinium salt redox systems for brain-targeted drug delivery provide a means for stabilizing the redox systems, particularly against oxidation. The redox inclusion complexes also provide a means for decreasing initial drug concentrations in the lungs after administration of the systems, leading to decreased toxicity. In selected instances, complexation results in substantially improved water solubility of the redox systems as well.

  羟丙基、羟乙基、葡萄糖基、麦芽糖基和麦芽三糖基的β-和γ-环糊精的包含物与二氢吡啶酰盐氧化还原体系的还原、可生物氧化、穿越血脑屏障的脂质形式形成的复合物，用于脑定向药物传递，提供了一种稳定氧化还原体系的手段，特别是对抗氧化反应。氧化还原的包含物复合物还提供了一种减少系统给药后肺部初始药物浓度的手段，从而降低毒性。在某些情况下，复合物化可显著提高氧化还原体系的水溶性。